Sign In
Buy RDUS
$10.08
+0 (+0%)
At Close: Jan 27, 2023
Why Radius Health Climbed Today
05:33pm, Thursday, 23'rd Jun 2022 The Motley Fool
It's getting acquired and taken private.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
05:18pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
02:40pm, Thursday, 23'rd Jun 2022
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
Why Radius Health Climbed Today
01:33pm, Thursday, 23'rd Jun 2022
It's getting acquired and taken private.
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
01:15pm, Thursday, 23'rd Jun 2022 GlobeNewswire Inc.
BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has entered into a definitive agreement to be ac
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
08:30pm, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
FLORENCE, Italy and BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) announced
Schnitzer Announces Third Quarter Fiscal 2022 Earnings Date and Conference Call Webcast Details
06:00pm, Thursday, 09'th Jun 2022
PORTLAND, Ore.--(BUSINESS WIRE)--Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) announced that the Company will report financial results for its third quarter fiscal 2022 ended May 31, 2022 on Wednes
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
02:03pm, Wednesday, 08'th Jun 2022 Benzinga
Upgrades
For Crescent Point Energy Corp (NYSE:CPG), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. In the first quarter, Crescent Point Energy showed an EPS of $0.32,
Radius Files Definitive Proxy and Mails Letter to Stockholders
11:30am, Monday, 06'th Jun 2022 GlobeNewswire Inc.
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
07:17pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
04:33pm, Thursday, 02'nd Jun 2022
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Radius Health Update on Abaloparatide Transdermal System
08:15pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the abaloparatide transdermal system (abalo-TDS) development pr
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
02:33pm, Monday, 23'rd May 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Motorola Solutions Inc (NYSE:MSI) was changed from Equal-Weight to Overweight. Motorola Solns earned $1.70 in the first quarter, compared to
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
04:54pm, Friday, 20'th May 2022 Zacks Investment Research
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
02:17pm, Friday, 20'th May 2022
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
